New ratings come amid soaring GLP-1 demand
— New ratings come amid soaring GLP-1 demand
August 12, 2026
• 2 min read
For the first time ever, U.S. News & World Report has released ratings of telehealth platforms offering GLP-1 weight-loss drugs.
The inaugural ratings evaluated 20 online platforms that offer FDA-approved, brand-name GLP-1 medications, such as semaglutide (Wegovy), tirzepatide (Zepbound), and orforglipron (Foundayo).
Many telehealth companies have emerged in recent years offering easy access to GLP-1 weight loss drugs as demand has exploded.…
A new Gallup poll found about 11% of Americans were taking a GLP-1 medication for weight loss.
The share of U.S. adults taking GLP-1 medications to lose weight has reached a record 11%.
A new secret-shopper study found that GLP-1 prescriptions from telehealth sites aren't often backed by appropriate clinical care.
Within 24 hours of injecting the first dose of a weight loss medication she received following a visit with a telehealth doctor,…
Around 36% of employers said they provide coverage of GLP-1s for both diabetes and weight loss, the same as 2025 and up from 34%…
